Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PRA International buys Spanish CRO (clinical research organisation):

This article was originally published in Clinica

Executive Summary

PRA International, the McLean, Virginia-based clinical research organisation (CRO), has acquired Staticon International Espana, a Madrid-based CRO, to expand its international network. Spain and Portugal are important clinical trial locations, David Thomas, vice-president and managing director of PRA's European operations told Clinica. PRA International conducts clinical trials and related services across a network of offices in the US, the UK, France, Germany, Spain and Poland. It also has partnerships in Latin America, South Africa, Australia and Asia. Of the $138 million revenues it expects in 2002, around 40% will be derived from its multi-country clinical trials. PRA also offers a number of complementary activities, including digitisation of medical images and specialised testing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel